可切除脑转移瘤术中放疗的系统综述与荟萃分析
1年局部控制率93%,1年远处脑控制率48%,中位总生存19个月,放射性坏死累积发生率2.6%。IORT毒性可控且局部控制良好,并可快速完成跨学科治疗以衔接后续抗肿瘤治疗。
要点
- 可切除脑转移瘤IORT的1年局部控制率达93%,中位总生存19个月。
- 放射性坏死累积发生率仅2.6%,软脑膜病变发生率6%,毒性谱良好。
- IORT后至脑转移以外下一次治疗的中位时间31天,显著短于SRT对照队列。
核心结论
- 可切除脑转移瘤患者接受IORT毒性谱良好且局部控制优异。
- IORT潜在优势是快速完成跨学科脑转移治疗,便于及时衔接后续抗肿瘤治疗。
- 尚需计划登记研究与前瞻性随机3期试验确定可切除脑转移瘤的首选放疗方式。
研究设计与样本
- 系统综述检索MEDLINE、Embase和Scopus数据库,纳入2015至2025年所有关于可切除脑转移瘤IORT的原创文章。
主要发现
- 77%的患者在手术和IORT时为单发脑转移。
- 中位施源器尺寸2.0 cm,中位处方剂量22.3 Gy(范围20-30 Gy)。
- 1年局部控制率93%,1年远处脑控制率48%,中位总生存19个月。
- 仅6%的患者发生软脑膜病变,放射性坏死累积发生率为2.6%(其中56%为1级)。
- 脑转移治疗以外下一次治疗的中位时间(范围)为31(1-136)天,显著短于SRT对照队列。
临床怎么用
- 对可切除脑转移瘤可考虑低能X线IORT作为术后SRT的替代方案,以缩短治疗周期并快速衔接后续治疗。
- IORT局部控制率高且放射性坏死和软脑膜病变风险低,支持其安全性。
局限性
- 纳入研究多为单臂设计(仅5项前瞻性单臂试验),证据等级有限。
- 中位随访仅14个月,部分研究随访范围宽(0-79个月),长期结局尚不确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In recent years, intraoperative radiotherapy (IORT) with low-energy X-rays is emerging as an alternative to postoperative stereotactic radiotherapy (SRT) of the resection cavity in patients with resectable brain metastases (BMs). METHODS: We performed a systematic review of the MEDLINE, Embase, and Scopus databases, including all original articles on IORT for resectable BMs from 2015 to 2025. Data on safety, local control, and survival outcomes were collected. RESULTS: Ten records (5 prospective single-arm trials) were included, representing 261 patients (49 % lung primary) with a median follow-up (range) of 14 (0-79) months. 77 % of patients had a solitary BM at the time of surgery and IORT. The median applicator size was 2.0 cm and the median prescribed dose (range) 22.3 (20-30) Gy. The 1-year local control rate was 93 % and the 1-year distant brain control rate 48 %. Median overall survival was 19 months. Only 6 % of patients developed leptomeningeal disease and the cumulative rate of radiation necrosis was 2.6 % (grade 1 in 56 % of cases). The median time to next treatment beyond BM therapy (range) was 31 (1-136) days. This was significantly shorter compared to SRT control collectives. CONCLUSIONS: IORT for patients with BMs has a favorable toxicity profile and yields excellent local control. A potential advantage is the rapid completion of interdisciplinary BM treatment, allowing a swift transition to subsequent cancer treatments. A planned registry and a prospective randomized phase 3 trial will establish the preferred radiotherapy modality in the context of resectable BMs.
引用
- Dejonckheere CS, Schneider M, Potthoff AL, et al. Intraoperative radiotherapy for resectable brain metastases: a systematic review and meta-analysis. Radiother Oncol. 2025. PMID: 40930278. doi:10.1016/j.radonc.2025.111128
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。